Skip to main content
$18.37 -$0.56 (-3.0%)

01:00 PM EST on 11/26/21

Coherus BioSciences, Inc. (NASDAQ:CHRS)

CAPS Rating: 2 out of 5

Current Price $18.37 Mkt Cap $1.4B
Open $18.65 P/E Ratio 0.00
Prev. Close $18.37 Div. (Yield) $0.00 (0.0%)
Daily Range $17.91 - $18.94 Volume 451,736
52-Wk Range $12.21 - $22.22 Avg. Daily Vol. 583,321

Caps

How do you think NASDAQ:CHRS will perform against the market?

Add Stock to CAPS Watchlist

All Players

31 Outperform
4 Underperform
 

All-Star Players

6 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CHRS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFTypeoh (95.74)
Submitted June 12, 2017

Pure-play biosimilar company. Getting killed on today's CRL. Company said no capital raise and issues can be fixed in a few months. Long-term thesis isn't busted (yet) so worth a green thumb in CAPS.

dlm777 (< 20)
Submitted July 14, 2017

nothing in the pipeline ?

NASDAQ:CHRS VS S&P 500 (SPY)

NASDAQ:CHRS Summary

Fools bullish on NASDAQ:CHRS are also bullish on:

Fools bearish on NASDAQ:CHRS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CHRS.

Recs

0
Member Avatar LazyHarlequin (88.42) Submitted: 7/8/2019 1:04:22 PM : Underperform Start Price: $17.87 NASDAQ:CHRS Score: +51.89

On 7/8/19 down $4+ to $19. Options available, but no LEAPs.

Recs

0
Member Avatar Bigsef77 (67.03) Submitted: 2/18/2019 9:42:19 AM : Outperform Start Price: $13.96 NASDAQ:CHRS Score: -34.22

Here's Why Coherus BioSciences Rose 48.7% in January
[Motley Fool]
Maxx Chatsko, The Motley Fool
,Motley Fool•February 11, 2019
What happened

Shares of Coherus BioSciences (NASDAQ: CHRS) gained nearly 49% last month, according to data provided by S&P Global Market Intelligence. The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. The pair had previously sparred over patents related to formulating the antibody.

The settlement gives Coherus Biosciences a license to the formulation patents, although it won't be able to sell CHS-1420 in the United States until December 2023. Additionally, it will have to provide royalties to AbbVie on all domestic sales just for using the patent portfolio. Given the size of the market, investors seem to think that won't matter in the end. Are they right?

Recs

1
Member Avatar dlm777 (< 20) Submitted: 7/14/2017 10:00:40 AM : Underperform Start Price: $13.85 NASDAQ:CHRS Score: +54.94

nothing in the pipeline ?

Leaderboard

Find the members with the highest scoring picks in CHRS.

Score Leader

murphydevani

murphydevani (< 20) Score: +163.17

The Score Leader is the player with the highest score across all their picks in CHRS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
murphydevani < 20 8/21/2015 Underperform 5Y $28.55 -35.66% +127.52% +163.17 1 Comment
dlm777 < 20 7/14/2017 Underperform 3M $13.85 +32.64% +87.58% +54.94 1 Comment
LazyHarlequin 88.42 7/8/2019 Underperform 5Y $17.87 +2.80% +54.69% +51.89 1 Comment
GW1000 85.37 7/23/2021 Outperform 5Y $13.00 +41.31% +4.40% +36.91 0 Comment
Hongkong < 20 6/2/2021 Outperform 3Y $13.17 +39.48% +9.18% +30.30 0 Comment
Jumpersfor 21.00 6/11/2021 Outperform 5Y $14.24 +29.00% +8.19% +20.82 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. WinWalk89 < 20 12/26/2017 Outperform 3Y $9.60 +91.35% +71.87% +19.49 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. rodas3 93.46 2/24/2021 Outperform 5Y $16.29 +12.77% +18.09% -5.32 0 Comment
chammond55 95.16 10/1/2021 Underperform 5Y $16.19 +13.47% +6.49% -6.97 0 Comment
gopvifootball < 20 3/28/2018 Outperform 1Y $10.90 +68.53% +76.02% -7.49 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CHRS.